Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 21 04:00PM ET
16.27
Dollar change
-0.78
Percentage change
-4.57
%
IndexRUT P/E- EPS (ttm)-3.07 Insider Own32.96% Shs Outstand10.79M Perf Week-12.24%
Market Cap183.07M Forward P/E- EPS next Y-2.32 Insider Trans0.00% Shs Float7.23M Perf Month-12.57%
Income-30.22M PEG- EPS next Q-0.65 Inst Own33.52% Short Float12.91% Perf Quarter-5.79%
Sales20.22M P/S9.05 EPS this Y6.27% Inst Trans-10.22% Short Ratio13.30 Perf Half Y-7.40%
Book/sh2.89 P/B5.64 EPS next Y18.40% ROA-43.19% Short Interest0.93M Perf Year3.43%
Cash/sh3.84 P/C4.24 EPS next 5Y19.12% ROE-96.33% 52W Range12.78 - 24.00 Perf YTD-8.60%
Dividend Est.- P/FCF- EPS past 5Y- ROI-80.24% 52W High-32.21% Beta0.46
Dividend TTM- Quick Ratio1.86 Sales past 5Y-6.42% Gross Margin13.03% 52W Low27.31% ATR (14)0.95
Dividend Ex-Date- Current Ratio1.97 EPS Y/Y TTM-300.13% Oper. Margin-95.85% RSI (14)40.83 Volatility5.12% 5.71%
Employees111 Debt/Eq0.22 Sales Y/Y TTM8.22% Profit Margin-149.46% Recom1.00 Target Price31.00
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q-91.64% Payout- Rel Volume3.42 Prev Close17.05
Sales Surprise1.49% EPS Surprise37.50% Sales Q/Q9.40% EarningsMar 19 BMO Avg Volume70.18K Price16.27
SMA20-5.71% SMA50-10.07% SMA200-7.71% Trades Volume239,922 Change-4.57%
Date Action Analyst Rating Change Price Target Change
Feb-28-25Initiated Craig Hallum Buy $39
Jul-16-24Reiterated Maxim Group Buy $25 → $30
Dec-22-22Initiated Maxim Group Buy $11
Jul-18-22Resumed Oppenheimer Outperform $7
Sep-23-20Initiated BTIG Research Buy $6
Nov-28-16Initiated Aegis Capital Buy $11
Aug-17-16Initiated Wells Fargo Outperform
Apr-16-14Initiated Oppenheimer Outperform $25
Mar-21-25 06:31PM
Mar-20-25 03:01AM
Mar-19-25 12:10PM
08:10AM
07:17AM
07:00AM Loading…
07:00AM
Mar-03-25 08:00AM
Feb-25-25 08:00AM
Feb-24-25 08:00AM
Feb-13-25 10:27AM
Feb-12-25 07:00AM
Feb-04-25 08:00AM
Jan-27-25 06:32AM
Jan-09-25 08:28AM
Dec-17-24 08:00AM
07:27AM Loading…
07:27AM
Nov-27-24 02:02AM
Nov-26-24 08:15AM
07:10AM
07:00AM
Nov-25-24 07:02AM
Nov-12-24 08:00AM
Oct-23-24 07:01PM
Oct-10-24 07:00AM
Oct-08-24 08:00AM
Sep-03-24 08:00AM
Aug-16-24 10:33AM
Aug-15-24 04:15PM
Aug-14-24 08:15AM
07:18AM
07:00AM Loading…
07:00AM
Aug-07-24 10:00AM
Aug-05-24 07:30AM
Aug-02-24 08:00AM
Jul-31-24 09:55AM
Jul-30-24 07:13AM
Jul-29-24 08:00AM
Jul-16-24 07:30AM
Jul-15-24 07:38AM
07:38AM
07:00AM
May-29-24 02:40PM
11:53AM
08:15AM
07:12AM
07:00AM
May-22-24 08:00AM
Apr-25-24 08:00AM
Apr-17-24 07:24AM
Mar-25-24 09:55AM
08:50AM
Mar-21-24 11:54AM
08:25AM
07:25AM
07:00AM
Mar-14-24 08:00AM
Mar-06-24 08:46AM
Feb-12-24 07:00AM
Feb-05-24 08:00AM
Jan-15-24 09:55AM
Jan-09-24 06:21PM
08:48AM
07:00AM
Dec-28-23 07:00AM
Dec-21-23 08:00AM
Dec-13-23 09:55AM
Nov-27-23 09:55AM
Nov-21-23 07:12AM
07:02AM
07:00AM
Nov-14-23 08:02AM
Nov-13-23 07:00AM
Nov-08-23 07:00AM
Oct-11-23 06:00AM
Oct-09-23 07:34AM
Oct-03-23 01:20PM
Sep-29-23 08:00AM
Sep-26-23 07:00AM
Sep-21-23 06:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:15PM
04:11PM
04:03PM
04:02PM
04:01PM
Aug-07-23 08:00AM
Aug-01-23 07:30AM
Jul-11-23 06:05AM
Jul-10-23 07:30AM
Jul-03-23 07:00AM
Jun-28-23 06:51AM
Jun-14-23 08:00AM
Jun-01-23 06:07AM
May-30-23 08:15AM
07:08AM
07:00AM
May-12-23 08:00AM
May-09-23 07:30AM
Apr-26-23 08:00AM
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.